drugset
drugset / Trial / NCT06102512

A Study of [14C]-LOXO-783 in Healthy Adult Participants

NCT06102512 ↗

Phase 1 Completed 16 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to evaluate how much of the study drug, the radioactive substance 14C incorporated LOXO-783 (\[¹⁴C\]-LOXO-783) passes from blood into urine, feces and expired air in healthy adult participants when administered as a single dose. The study will also measure how much of the LOXO-783 and \[¹⁴C\]-LOXO-783 gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study is conducted in two parts and will last up to approximately 72 and 61 days for part 1 and 2, respectively.

Timeline

Start
2023-10-23
Primary completion
2023-12-23
Completion
2024-01-17

Drugs

EvaluationDrugModalityDoseRoute
Subject LOXO-783 Unknown — Oral

Indications

No indication recorded.